Eighty percent mortality occurs in patients with type 2 diabetes mellitus due to cardiovascular (CV) events like myocardial infarction, stroke and peripheral vascular disease. We learned from United Kingdom Prospective Diabetes Study (UKPDS) that lowering HbA1c reduces both micro and macrovascular complications. However, more recent studies have provided insight that HbA1c reduction may exert only a modest effect in lowering macrovascular complications. In fact, treating hypertension and dyslipidemia may provide a greater benefit in reducing CV events. The last 10 years have changed our understanding of cardiovascular disease (CVD) risk in type 2 diabetes. Earlier it was believed to be due to atherosclerotic cardiovascular disease which was exaggerated by hyperglycemia. Additionally, some antidiabetic medications were also implied to contribute to cardiovascular illness and mortality. It is plausible that insulin resistance may play a significant role in cardiovascular complications as well since it induces endothelial dysfunction much earlier before type 2 diabetes is diagnosed. Many patients manifest CVD in form of either atherosclerotic cardiovascular disease (ASCVD) or heart failure prior to diagnosis of diabetes. Amelioration of insulin resistance may be the management key in type 2 diabetes and can be very well achieved with modern drugs although attaining and maintaining desirable glycemic control may be as crucial as noted in type 1 diabetes.
References
[1]
Matheus, A.S., Tannus, L.R., Cobas, R.A., et al. (2013) Impact of Diabetes on Cardiovascular Disease: An Update. International Journal of Hypertension, 2013, Article ID: 653789. https://doi.org/10.1155/2013/653789
[2]
Hsueh, W.A. and Law, R.E. (1998) Cardiovascular Risk Continuum: Implications of Insulin Resistance and Diabetes. American Journal of Medicine, 105, 4S-14S. https://doi.org/10.1016/S0002-9343(98)00205-8
[3]
Mohan, V., Shanthirani, C.S., Deepa, M., et al. (2006) Mortality Rates Due to Diabetes in a Selected Urban South Indian Population—The Chennai Urban Population Study [CUPS-16]. Journal of the Association of Physicians of India, 54, 113-117.
[4]
Holman, R.R., Paul, S.K., Bethel, M.A., et al. (2008) 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 359, 1577-1589. https://doi.org/10.1056/NEJMoa0806470
[5]
Morrish, N.J., Wang, S.L., Stevens, L.K., Fuller, J.H. and Keen, H. (2001) Mortality and Causes of Death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia, 44, Article No. S14. https://doi.org/10.1007/PL00002934
[6]
Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine, 358, 2545-2559. https://doi.org/10.1056/NEJMoa0802743
[7]
ADVANCE Collaborative Group (2008) Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 358, 2560-2572. https://doi.org/10.1056/NEJMoa0802987
[8]
Duckworth, W., Abraira, C., Moritz, T., et al. (2009) VADT Investigators. Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes. New England Journal of Medicine, 360, 129-139. https://doi.org/10.1056/NEJMoa0808431
[9]
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). Lancet, 352, 837-853. https://doi.org/10.1016/S0140-6736(98)07019-6
[10]
Colhoun, H.M., Betteridge, D.J., Durrington, P.N., et al. on Behalf of the CARDS Investigators (2004) Primary Prevention of Cardiovascular Disease with Atorvastatin in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre Randomised Placebo-Controlled Trial. Lancet, 364, 685-696. https://doi.org/10.1016/S0140-6736(04)16895-5
[11]
Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of Ramipril on Cardiovascular and Microvascular Outcomes in People with Diabetes Mellitus: Results of the HOPE Study and MICRO-HOPE Substudy. Lancet, 355, 253-259. https://doi.org/10.1016/S0140-6736(99)12323-7
[12]
Bell, D.S.H. (2006) Do sulfonylurea Drugs Increase the Risk of Cardiac Events? Canadian Medical Association Journal, 174, 185-186. https://doi.org/10.1503/cmaj.051237
[13]
Frier, B.M., Schernthaner, G., Heller, S.R. (2011) Hypoglycemia and Cardiovascular Risks. Diabetes Care, 34, S132-S137. https://doi.org/10.2337/dc11-s220
[14]
Kaul, S., Bolger, A.F., Herrington, D., et al. (2010) Thiazolidinedione Drugs and Cardiovascular Risks: A Science Advisory from the American Heart Association and American College of Cardiology Foundation. Circulation, 121, 1868-1877. https://doi.org/10.1161/CIR.0b013e3181d34114
[15]
Del Prato, S., Bianchi, C., Dardano, A., et al. (2013) Insulin as an Early Treatment for Type 2 Diabetes. Origin or End of an Old Question? Diabetes Care, 36, S198-S204. https://doi.org/10.2337/dcS13-2019
[16]
Yu, J.H., Han, K., Park, S., Lee, D.Y., Nam, G.E., Seo, J.A., Kim, S.G., Baik, S.H., Park, Y.G., Kim, S.M., Kim, N.H. and Choi, K.M. (2019) Effects of Long-Term Glycemic Variability on Incident Cardiovascular Disease and Mortality in Subjects without Diabetes. Medicine, 98, Article ID: e16317. https://doi.org/10.1097/MD.0000000000016317
[17]
Su, G., Mi, S., Tao, H., et al. (2011) Association of Glycemic Variability and the Presence and Severity of Coronary Artery Disease in Patients with Type 2 Diabetes. Cardiovascular Diabetology, 10, Article No. 19. https://doi.org/10.1186/1475-2840-10-19
[18]
Hirshberg, B. and Katz, A. (2013) Cardiovascular Outcome Studies with Novel Antidiabetes Agents: Scientific and Operational Considerations. Diabetes Care, 36, S253-S258. https://doi.org/10.2337/dcS13-2041
[19]
DeFronzo, R.A. (2010) Insulin Resistance, Lipotoxicity, Type 2 Diabetes and Atherosclerosis: The Missing Links. The Claude Bernard Lecture 2009. Diabetologia, 53, 1270-1287. https://doi.org/10.1007/s00125-010-1684-1
[20]
Obunai, K., Jani, S. and Dangas, G.D. (2007) Cardiovascular Morbidity and Mortality of the Metabolic Syndrome. Medical Clinics of North America, 91, 1169-1184. https://doi.org/10.1016/j.mcna.2007.06.003
[21]
Ghani, M.A., DeFronzo, R.A., Prato, S.D., Chilton, R., Singh, R. and Ryder, R.E.J. (2017) Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care, 40, 813-820. https://doi.org/10.2337/dc16-2736
[22]
Kernan, W.N., Viscoli, C.M., Furie, K.L., et al., for the IRIS Trial Investigators. (2016) Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. New England Journal of Medicine, 374, 1321-1331. https://doi.org/10.1056/NEJMoa1506930
[23]
Nissen, S.E. and Wolski, K. (2007) Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. New England Journal of Medicine, 356, 2457-2471. https://doi.org/10.1056/NEJMoa072761
[24]
Home, P.D., Pocock, S.J., Beck-Nielsen, H., Curtis, P.S., Gomis, R., Hanefeld, M., Jones, N.P., Komajda, M. and McMurray, J.J.V. (2009) RECORD Study Team Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD): A Multicentre, Randomised, Open-Label Trial. Lancet, 373, 2125-2135. https://doi.org/10.1016/S0140-6736(09)60953-3
[25]
Eldor, R., DeFronzo, R.A. and Abdul-Ghani, M. (2013) In Vivo Actions of Peroxisome Proliferator-Activated Receptors: Glycemic Control, Insulin Sensitivity, and Insulin Secretion. Diabetes Care, 36, S162-S174. https://doi.org/10.2337/dcS13-2003
[26]
Merovci, A., Solis-Herrera, C., Daniele, G., et al. (2014) Dapagliflozin Improves Muscle Insulin Sensitivity but Enhances Endogenous Glucose Production. Journal of Clinical Investigation, 124, 509-514. https://doi.org/10.1172/JCI70704
[27]
Nathan, D.M., for the DCCT/EDIC Research Group (2014) The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview. Diabetes Care, 37, 9-16. https://doi.org/10.2337/dc13-2112
[28]
Kabadi, U.M. (2017) Cardiovascular Outcome Trials in Type 2 Diabetes: Reliable or Biased! World Journal of Pharmaceutical and Medical Research 3, 33-35.
[29]
Shimazawa, R. and Ikeda, M. (2019) Imbalance in Glycemic Control between the Treatment and Placebo Groups in Cardiovascular Outcome Trials in Type 2 Diabetes. Journal of Pharmaceutical Policy and Practice, 12, Article No. 30. https://doi.org/10.1186/s40545-019-0193-y
[30]
Kabadi Udaya, M. (2021) Comparative Effectiveness of Glucose lowering Drugs for Type 2 Diabetes. Annals of Internal Medicine, 174, 140. https://doi.org/10.7326/L20-1277
[31]
Kabadi Udaya, M. (2021) Improvement in Cardiovascular and Renal Outcomes in Type 2 Diabetes: Effect of Glycemic Control, not Drugs. Journal of Diabetes, Metabolic Disorders & Control, 8, 76-77. https://doi.org/10.15406/jdmdc.2021.08.00225
[32]
Kabadi, U.M. (2021) Diabetes Mellitus: Disorder of Cellular Dysfunction Due to Lack of Entry into Cell of Glucose. The Most Efficient Fuel for Cellular Function. Open Journal of Endocrine and Metabolic Diseases, 11, 79-101. https://doi.org/10.4236/ojemd.2021.113007
[33]
Verma, S., Garg, A., Yan, A.T., et al. (2016) Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals with Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial? Diabetes Care, 39, e212-e213. https://doi.org/10.2337/dc16-1312
[34]
Abdul-Ghani, M., Del Prato, S., Chilton, R. and DeFronzo, R.A. (2016) SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned from the EMPA-REG OUTCOME Study. Diabetes Care, 39, 717-725. https://doi.org/10.2337/dc16-0041
